Biotech Values

[DewDiligence]

>A quick glance tells me the only real Prostate Cancer expert on the panel is Maha Hussain - I could be wrong, the rest are more like breast cancer specialists, because I think the focus of this ODAC is Lilly's EVISTA<

The Evista application in breast cancer is a biggie, so you are right: it will grab most of the attention next week despite the high level of interest in Satraplatin on biotech message boards such as this one. The question of whether Evista is better than Tamoxifen in breast cancer prevention has been debated for almost ten years.